Agomelatine in unipolar depression in clinical practice: A retrospective chart review

Therapeutic Advances in Psychopharmacology

Volumn 1, Issue 6, 2011, Pages 175-180

  Langan, Julie ^a   Shajahan, Polash ^a   Martin, Daniel ^a   Carleton, Rebecca ^a  

^a NONE

Author keywords

agomelatine; depression; polypharmacy; retrospective

Indexed keywords

AGOMELATINE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; NEUROLEPTIC AGENT; PREGABALIN; PSYCHOTROPIC AGENT; SEROTONIN ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; ELECTRONIC MEDICAL RECORD; FEMALE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; MALE; MEDICAL RECORD REVIEW; MENTAL PATIENT; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84998044271     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311423296     Document Type: Article

References (33)

1. Armitage R. Hoffman R.f. Emslie G.J. Weinberg W.A. Mayes T.L. Rush A.J. (2002) Sleep microarchitecture as a predictor of recurrence in children and adolescents with depression. Int Neuropsychopharmacol 5: 217–228.
2. Barbee J.G. Corad E.J. Jamhour N.J. (2004) The effectiveness of olanzapine, risperidone, quetiapine and ziprasidone as augmentation agents in treatment-refractory major depressive disorder. J Clin Psychiatry 65: 975–981.
3. Benca R.M. Obermeyer W.H. Thisted R.A. Gililin J.C. (1992) Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry 49: 651–659.
4. Berlim M.T. Turecki G. (2007) Definition, assessment and staging of treatment refractory major depression: a review of current concepts and methods. Can J Psychiatry 52: 46–54.
5. Busner J. Targum S.D. (2007) The Clinical Global Impressions Scale: Applying a research tool in clinical practice. Innovations in Clinical Neuroscience 7: 28–37.
6. Buysee D.J. Frank E. Lowe K. Cherry C.R. Kupfer D.J. (1997) Electroencephalographic sleep correlates of episode and vulnerability to recurrence in depression. Biol Psychiatry 41: 406–418.
7. Calabrese J.R. Guelfi J.D. Perdrizet-Chevallier C. (2007) Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord 9: 628–635.
8. Centorrino F. Fogarty K.V. Cimbolli P. Salvatore P. Thompson T.A. Sanj G. Cincotta S.L. Baldessarini R.J. (2005) Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 11: 241–247.
9. Den Boer J.A. Bosker F.J. Meesters Y. (2006) Clinical efficacy of agomelatine in depression: the evidence. International Clinical Psychopharmacology 21(Suppl. 1): S21–S24.
10. European Public Assessment Report (EPAR) for Valdoxan. Available at: http://www.emea.europa.eu (accessed 9 December 2010).
11. Goodwin G.M. Emsley R. Rembry S. Rouillon F. (2009) Agomelatine presents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24 week randomised, double blind placebo controlled trial. Agomelatine Study Group. J Clin Psychiatry 70: 1128–1137.
12. Hale A. Corral R.M. Mencacci C. Severo C.A. Gentil V. (2010) Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. Int Clin Psychopharmacol 25: 305–314.
13. Kasper S. Hajak G. Wulff K. Hoogendijk W.J. Montejo A.L. Smeraldi E. Rybakowski J.K. Quera-Salva M.A. Wirz-Justice A.M. Picarel-Blanchot F. Baylé F.J. (2010) Efficacy of the novel anti-depressant on the circadian rest activity cycle and depression and anxiety symptoms in patients with major depressive disorder without evidence of a randomised double blind comparison with sertraline. J Clin Psychiatry 71: 109–120.
14. Kennedy. (2009) Review article: Agomelatine efficacy at each phase of antidepressant activity. CNS Drugs 23(Suppl. 2): 41–47.
15. Lemoine P. Guilleminault C. Alvarez E. (2007) Improvement in subjective sleep in major depressive disorder with a novel anti-depressant, agomelatine: randomised, double blind comparison with venlafaxine. J Clin Psychiatry 68: 1723–1732.
16. Licht R.W. Qvitzau S. (2002) Treatment strategies in patients with major depression not responding to first line sertraline: a randomised study of extended duration of treatment, dose increase or augmentation with minaserin. Psychopharmacology 161: 143–151.
17. Lopes M.C. Quera-Salva M.A. Guilleminault C. (2007) Non- REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non REM sleep instability with treatment (agomelatine). Sleep Med 9: 33–41.
18. Mojtabai. (2010) National trends in psychotropic medication polypharmacy in office based psychiatry. Arch Gen Psychiatry 67: 26–36.
19. Montgomery. (2006) Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur J Neuropsychopharmacol 16: S633–S638.
20. Olié J.P. Kasper S (2007) Efficacy of agomelatine, a MT1/MT2receptor agonist with 5HT2c antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10: 661–673.
21. Pjrek E. Winkler D. Konstantinidis A. Willeit M. Praschak-Rieder N. Kasper S. (2007) Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 190: 575–579.
22. Quera Salva M.A. Vanier B. Laredo J. Hartley S. Chapotot F. Moulin C. Lofaso F. Guilleminault C. (2007) Major depressive disorder, sleep EEG and agomelatine: an open label study. Int J Neuropsychopharmacol 10: 691–696.
23. Rouillon. (2006) Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 21(Suppl. 1): S31–S35.
24. Shajahan P. Macrae A. Bashir M. Taylor M. (2008) Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol 22: 778–783.
25. Shelton. (2003) The use of anti-depressants in novella combinations. J Clin Psychiatry 64(Suppl. 2): 14–18.
26. Stahl S.M. Fava M. Trivedi M.H. Caputo A. Shah A. Post A. (2010) Agomelatine in the treatment of major depressive disorder: an 8 week, multi-centre, randomized placebo controlled trial. J Clin Psychiatry 71: 616–626.
27. Stein D.J. Ahokas A.A. De Bodinat C. (2008) Efficacy of agomelatine in generalised anxiety disorder: a randomised, double blind, placebo controlled study. J Clin Psychopharmacol 28: 561–565.
28. Stimpson N. Agrawal N. Lewis G. (2002) Randomized controlled trials investigating pharmacological and psychological interventions for treatment-refractory depression: systematic review. Br J Psychiatry 181: 284–294.
29. Schulze-Rauschenbach S.C. Harms U. Schlaepfer T.E. Maier W. Falkai P. Wagner M. (2005) Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. British Journal of Psychiatry 186: 410–416.
30. Taylor D. Paton C. Kapur S. (2009) The Maudsley Prescribing Guidelines, edition 10, p. 178.
31. Thase. (2005) Bipolar depression: issues in diagnosis and treatment. Harvard Rev Psychiatry 13: 257–271.
32. Waddington J.L. Youssef H.A. Kinsella A. (1998) Mortality in schizophrenia. Anti-psychotic polypharmacy and absence of adjunctive anti-cholinergics over the course of a 10 year prospective study. Br J Psychiatry 173: 325–329.
33. Wheeler Vega J.A. Mortimer M. Tyson P.J. (2003) Conventional anti-psychotic use in unipolar depression: an audit and recommendations for practice. J Clin Psychiatry 64: 568–574.